Evaluation of the changes on hemostatic parameters induced by valdecoxib in male Wistar rats

Revista Brasileira de Hematologia e Hemoterapia

Volumn 28, Issue 1, 2006, Pages 28-32

  Fronza, Marcio ^c   Wrasse, Micheli ^c   Brum Jr , Liberato ^c   Sangoi, Maximiliano S ^c   Dalmora, Sérgio L ^a,b,c  

^a Industrial Pharmacy Department   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Coagulation; Factor Xa; Liquid chromatography; Rats; Valdecoxib

Indexed keywords

EID: 33747342364     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842006000100008     Document Type: Article

References (14)

1. Stassen JM, Nystrom A. A historical review of hemostasis, thrombosis, and antithrombotic therapy. Ann Plast Surg 1997;39:317-29.
2. Talley JJ, Brown DL, Carter JS et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A potent and selective inhibitor of COX-2. J Med Chem 2000;43:775-7.
3. Catella-Lawson F, Crofford LJ. Cyclooxygenase Inhibition and Thrombogenicity. Am J Med 2001;110:28-32.
4. Fitzgerald GA. Coxibs and cardiovascular disease. N Engl J Med 2004;351:1709-11.
5. Topol EJ. Arthritis Medicines and Cardiovascular Events - "House of Coxibs". JAMA 2005;293:366-8.
6. Howard PA, Delafontaine P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk. J Am Coll Cardiol 2004;43:519-25.
7. Bennett JS, Daugherty A, Herrington D et al. The use of nonsteroidal anti-inflammatory drugs (NSAIDs). Circulation 2005;111:1.713-16.
8. Konstantinopoulos PA, Lehmann DF. The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: Comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005;45:742-50.
9. Hull MA. Cyclooxygenase-2: How good is it as a target for cancer chemoprevention? Eur J Cancer 2005; In press.
10. Vaccari SF, Brum Junior L, Masiero SMK et al. Avaliação comparativa da atividade de heparinas não-fracionadas em produtos farmacêuticos. Rev Bras Hematol Hemoter 2003;25:103-10.
11. Dalmora SL, Brum Junior L, Fronza M et al. Validation of the anti-factor IIa assay and potency assessment of enoxaparin in pharmaceutical formulations. Il Farmaco 2005; 60:225-9.
12. Doutremepuich F, Aguejouf O, Imbault P et al. Effect of the low molecular weight heparin/non steroidal anti-inflammatory drugs association on an experimental thrombosis induced by laser. Thromb Res 1995;77:311-9.
13. Product Information: Bextra®, Valdecoxib. Pharmacia Corporation, Chicago, Il, (PI developed 11/2001) reviewed 11/2001.
14. O'Shaughnessy D, Makris M, Lillicrap D. Practical Hemostasis and Thrombosis. Oxford, United Kingdom: Blackwell Publishing 2005, 224p.